Pharma & Healthcare
Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Research Report 2026
- Feb 03, 26
- ID: 702509
- Pages: 131
- Figures: 131
- Views: 9
This report delivers a comprehensive overview of the global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Long-acting Granulocyte-Colony Stimulating Factor (G-CSF). The Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Amgen
Mylan
Kashiv BioSciences
Pfizer
Fresenius Kabi
Coherus BioSciences
Sandoz
Italfarmaco SpA
Evive Biotech
Chugai Pharmaceutical
Jiangsu Hengrui Pharmaceuticals
Amoytop Biotech
Qilu Pharmaceutical
CSPC Baike Biopharma
SL Pharm
Lunan Pharmaceutical
Segment by Type
Pegfilgrastim
Lenograstim
Other
by Application
Hospital and Clinic
Pharmacy
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
The report segments the global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Amgen
Mylan
Kashiv BioSciences
Pfizer
Fresenius Kabi
Coherus BioSciences
Sandoz
Italfarmaco SpA
Evive Biotech
Chugai Pharmaceutical
Jiangsu Hengrui Pharmaceuticals
Amoytop Biotech
Qilu Pharmaceutical
CSPC Baike Biopharma
SL Pharm
Lunan Pharmaceutical
Segment by Type
Pegfilgrastim
Lenograstim
Other
by Application
Hospital and Clinic
Pharmacy
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
1 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Overview
1.1 Product Definition
1.2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) by Type
1.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Value by Type: 2025 vs 2032
1.2.2 Pegfilgrastim
1.2.3 Lenograstim
1.2.4 Other
1.3 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) by Application
1.3.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Value by Application: 2025 vs 2032
1.3.2 Hospital and Clinic
1.3.3 Pharmacy
1.3.4 Other
1.4 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size Estimates and Forecasts
1.4.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue 2021–2032
1.4.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales 2021–2032
1.4.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Competition by Manufacturers
2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Manufacturers (2021–2026)
2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), Product Types and Applications
2.7 Global Key Manufacturers of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), Date of Entry into the Industry
2.8 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Competitive Situation and Trends
2.8.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Players Market Share by Revenue
2.8.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Scenario by Region
3.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region: 2021–2032
3.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region: 2021–2026
3.2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region: 2027–2032
3.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region: 2021–2032
3.3.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region: 2021–2026
3.3.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region: 2027–2032
3.4 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Facts & Figures by Country
3.4.1 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021–2032)
3.4.3 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Facts & Figures by Country
3.5.1 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021–2032)
3.5.3 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Facts & Figures by Region
3.6.1 Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (2021–2032)
3.6.3 Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Facts & Figures by Country
3.7.1 Latin America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021–2032)
3.7.3 Latin America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Facts & Figures by Country
3.8.1 Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021–2032)
3.8.3 Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021–2032)
4.1.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021–2026)
4.1.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2027–2032)
4.1.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2021–2032)
4.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2021–2032)
4.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2021–2026)
4.2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2027–2032)
4.2.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Type (2021–2032)
4.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Type (2021–2032)
5 Segment by Application
5.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021–2032)
5.1.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021–2026)
5.1.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2027–2032)
5.1.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Application (2021–2032)
5.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2021–2032)
5.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2021–2026)
5.2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2027–2032)
5.2.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Application (2021–2032)
5.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Amgen
6.1.1 Amgen Company Information
6.1.2 Amgen Description and Business Overview
6.1.3 Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.1.5 Amgen Recent Developments/Updates
6.2 Mylan
6.2.1 Mylan Company Information
6.2.2 Mylan Description and Business Overview
6.2.3 Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.2.5 Mylan Recent Developments/Updates
6.3 Kashiv BioSciences
6.3.1 Kashiv BioSciences Company Information
6.3.2 Kashiv BioSciences Description and Business Overview
6.3.3 Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.3.5 Kashiv BioSciences Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Company Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Fresenius Kabi
6.5.1 Fresenius Kabi Company Information
6.5.2 Fresenius Kabi Description and Business Overview
6.5.3 Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.5.5 Fresenius Kabi Recent Developments/Updates
6.6 Coherus BioSciences
6.6.1 Coherus BioSciences Company Information
6.6.2 Coherus BioSciences Description and Business Overview
6.6.3 Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.6.5 Coherus BioSciences Recent Developments/Updates
6.7 Sandoz
6.7.1 Sandoz Company Information
6.7.2 Sandoz Description and Business Overview
6.7.3 Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.7.5 Sandoz Recent Developments/Updates
6.8 Italfarmaco SpA
6.8.1 Italfarmaco SpA Company Information
6.8.2 Italfarmaco SpA Description and Business Overview
6.8.3 Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.8.5 Italfarmaco SpA Recent Developments/Updates
6.9 Evive Biotech
6.9.1 Evive Biotech Company Information
6.9.2 Evive Biotech Description and Business Overview
6.9.3 Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.9.5 Evive Biotech Recent Developments/Updates
6.10 Chugai Pharmaceutical
6.10.1 Chugai Pharmaceutical Company Information
6.10.2 Chugai Pharmaceutical Description and Business Overview
6.10.3 Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.10.5 Chugai Pharmaceutical Recent Developments/Updates
6.11 Jiangsu Hengrui Pharmaceuticals
6.11.1 Jiangsu Hengrui Pharmaceuticals Company Information
6.11.2 Jiangsu Hengrui Pharmaceuticals Description and Business Overview
6.11.3 Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.11.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
6.12 Amoytop Biotech
6.12.1 Amoytop Biotech Company Information
6.12.2 Amoytop Biotech Description and Business Overview
6.12.3 Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.12.5 Amoytop Biotech Recent Developments/Updates
6.13 Qilu Pharmaceutical
6.13.1 Qilu Pharmaceutical Company Information
6.13.2 Qilu Pharmaceutical Description and Business Overview
6.13.3 Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.13.5 Qilu Pharmaceutical Recent Developments/Updates
6.14 CSPC Baike Biopharma
6.14.1 CSPC Baike Biopharma Company Information
6.14.2 CSPC Baike Biopharma Description and Business Overview
6.14.3 CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.14.5 CSPC Baike Biopharma Recent Developments/Updates
6.15 SL Pharm
6.15.1 SL Pharm Company Information
6.15.2 SL Pharm Description and Business Overview
6.15.3 SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, and Gross Margin (2021–2026)
6.15.4 SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.15.5 SL Pharm Recent Developments/Updates
6.16 Lunan Pharmaceutical
6.16.1 Lunan Pharmaceutical Company Information
6.16.2 Lunan Pharmaceutical Description and Business Overview
6.16.3 Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, and Gross Margin (2021–2026)
6.16.4 Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.16.5 Lunan Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Chain Analysis
7.2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Production Mode & Process Analysis
7.4 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Marketing
7.4.1 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Channels
7.4.2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Distributors
7.5 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Customer Analysis
8 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Dynamics
8.1 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Trends
8.2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Drivers
8.3 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Challenges
8.4 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) by Type
1.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Value by Type: 2025 vs 2032
1.2.2 Pegfilgrastim
1.2.3 Lenograstim
1.2.4 Other
1.3 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) by Application
1.3.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Value by Application: 2025 vs 2032
1.3.2 Hospital and Clinic
1.3.3 Pharmacy
1.3.4 Other
1.4 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size Estimates and Forecasts
1.4.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue 2021–2032
1.4.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales 2021–2032
1.4.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Competition by Manufacturers
2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Manufacturers (2021–2026)
2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), Product Types and Applications
2.7 Global Key Manufacturers of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), Date of Entry into the Industry
2.8 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Competitive Situation and Trends
2.8.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Players Market Share by Revenue
2.8.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Scenario by Region
3.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region: 2021–2032
3.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region: 2021–2026
3.2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region: 2027–2032
3.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region: 2021–2032
3.3.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region: 2021–2026
3.3.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region: 2027–2032
3.4 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Facts & Figures by Country
3.4.1 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021–2032)
3.4.3 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Facts & Figures by Country
3.5.1 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021–2032)
3.5.3 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Facts & Figures by Region
3.6.1 Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (2021–2032)
3.6.3 Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Facts & Figures by Country
3.7.1 Latin America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021–2032)
3.7.3 Latin America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Facts & Figures by Country
3.8.1 Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021–2032)
3.8.3 Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021–2032)
4.1.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021–2026)
4.1.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2027–2032)
4.1.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2021–2032)
4.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2021–2032)
4.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2021–2026)
4.2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2027–2032)
4.2.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Type (2021–2032)
4.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Type (2021–2032)
5 Segment by Application
5.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021–2032)
5.1.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021–2026)
5.1.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2027–2032)
5.1.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Application (2021–2032)
5.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2021–2032)
5.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2021–2026)
5.2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2027–2032)
5.2.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Application (2021–2032)
5.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Amgen
6.1.1 Amgen Company Information
6.1.2 Amgen Description and Business Overview
6.1.3 Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.1.5 Amgen Recent Developments/Updates
6.2 Mylan
6.2.1 Mylan Company Information
6.2.2 Mylan Description and Business Overview
6.2.3 Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.2.5 Mylan Recent Developments/Updates
6.3 Kashiv BioSciences
6.3.1 Kashiv BioSciences Company Information
6.3.2 Kashiv BioSciences Description and Business Overview
6.3.3 Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.3.5 Kashiv BioSciences Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Company Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Fresenius Kabi
6.5.1 Fresenius Kabi Company Information
6.5.2 Fresenius Kabi Description and Business Overview
6.5.3 Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.5.5 Fresenius Kabi Recent Developments/Updates
6.6 Coherus BioSciences
6.6.1 Coherus BioSciences Company Information
6.6.2 Coherus BioSciences Description and Business Overview
6.6.3 Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.6.5 Coherus BioSciences Recent Developments/Updates
6.7 Sandoz
6.7.1 Sandoz Company Information
6.7.2 Sandoz Description and Business Overview
6.7.3 Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.7.5 Sandoz Recent Developments/Updates
6.8 Italfarmaco SpA
6.8.1 Italfarmaco SpA Company Information
6.8.2 Italfarmaco SpA Description and Business Overview
6.8.3 Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.8.5 Italfarmaco SpA Recent Developments/Updates
6.9 Evive Biotech
6.9.1 Evive Biotech Company Information
6.9.2 Evive Biotech Description and Business Overview
6.9.3 Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.9.5 Evive Biotech Recent Developments/Updates
6.10 Chugai Pharmaceutical
6.10.1 Chugai Pharmaceutical Company Information
6.10.2 Chugai Pharmaceutical Description and Business Overview
6.10.3 Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.10.5 Chugai Pharmaceutical Recent Developments/Updates
6.11 Jiangsu Hengrui Pharmaceuticals
6.11.1 Jiangsu Hengrui Pharmaceuticals Company Information
6.11.2 Jiangsu Hengrui Pharmaceuticals Description and Business Overview
6.11.3 Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.11.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
6.12 Amoytop Biotech
6.12.1 Amoytop Biotech Company Information
6.12.2 Amoytop Biotech Description and Business Overview
6.12.3 Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.12.5 Amoytop Biotech Recent Developments/Updates
6.13 Qilu Pharmaceutical
6.13.1 Qilu Pharmaceutical Company Information
6.13.2 Qilu Pharmaceutical Description and Business Overview
6.13.3 Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.13.5 Qilu Pharmaceutical Recent Developments/Updates
6.14 CSPC Baike Biopharma
6.14.1 CSPC Baike Biopharma Company Information
6.14.2 CSPC Baike Biopharma Description and Business Overview
6.14.3 CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.14.5 CSPC Baike Biopharma Recent Developments/Updates
6.15 SL Pharm
6.15.1 SL Pharm Company Information
6.15.2 SL Pharm Description and Business Overview
6.15.3 SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, and Gross Margin (2021–2026)
6.15.4 SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.15.5 SL Pharm Recent Developments/Updates
6.16 Lunan Pharmaceutical
6.16.1 Lunan Pharmaceutical Company Information
6.16.2 Lunan Pharmaceutical Description and Business Overview
6.16.3 Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue, and Gross Margin (2021–2026)
6.16.4 Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
6.16.5 Lunan Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Chain Analysis
7.2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Production Mode & Process Analysis
7.4 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales and Marketing
7.4.1 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Channels
7.4.2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Distributors
7.5 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Customer Analysis
8 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Dynamics
8.1 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Trends
8.2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Drivers
8.3 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Challenges
8.4 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Competitive Situation by Manufacturers in 2025
Table 4. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), Product Types and Applications
Table 12. Global Key Manufacturers of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Companies by Tier (Tier 1, Tier 2, Tier 3), based on Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (K Units), 2021–2026
Table 18. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Region (2021–2026)
Table 19. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (K Units), 2027–2032
Table 20. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Region (2027–2032)
Table 21. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region (US$ Million), 2021–2026
Table 22. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Region (2021–2026)
Table 23. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region (US$ Million), 2027–2032
Table 24. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Region (2027–2032)
Table 25. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (K Units), 2021–2026
Table 27. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (K Units), 2027–2032
Table 28. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (US$ Million), 2021–2026
Table 29. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (K Units), 2021–2026
Table 32. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (K Units), 2027–2032
Table 33. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (K Units), 2021–2026
Table 42. Latin America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (K Units), 2027–2032
Table 43. Latin America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (US$ Million), 2027–2032
Table 50. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units) by Type (2021–2026)
Table 51. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units) by Type (2027–2032)
Table 52. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2021–2026)
Table 53. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2027–2032)
Table 54. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Type (2021–2026)
Table 57. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Type (2027–2032)
Table 58. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price (US$/Unit) by Type (2021–2026)
Table 59. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price (US$/Unit) by Type (2027–2032)
Table 60. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units) by Application (2021–2026)
Table 61. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units) by Application (2027–2032)
Table 62. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Application (2021–2026)
Table 63. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Application (2027–2032)
Table 64. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Application (2021–2026)
Table 67. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Application (2027–2032)
Table 68. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price (US$/Unit) by Application (2021–2026)
Table 69. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price (US$/Unit) by Application (2027–2032)
Table 70. Amgen Company Information
Table 71. Amgen Description and Business Overview
Table 72. Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
Table 74. Amgen Recent Developments/Updates
Table 75. Mylan Company Information
Table 76. Mylan Description and Business Overview
Table 77. Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
Table 79. Mylan Recent Developments/Updates
Table 80. Kashiv BioSciences Company Information
Table 81. Kashiv BioSciences Description and Business Overview
Table 82. Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
Table 84. Kashiv BioSciences Recent Developments/Updates
Table 85. Pfizer Company Information
Table 86. Pfizer Description and Business Overview
Table 87. Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
Table 89. Pfizer Recent Developments/Updates
Table 90. Fresenius Kabi Company Information
Table 91. Fresenius Kabi Description and Business Overview
Table 92. Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
Table 94. Fresenius Kabi Recent Developments/Updates
Table 95. Coherus BioSciences Company Information
Table 96. Coherus BioSciences Description and Business Overview
Table 97. Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
Table 99. Coherus BioSciences Recent Developments/Updates
Table 100. Sandoz Company Information
Table 101. Sandoz Description and Business Overview
Table 102. Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
Table 104. Sandoz Recent Developments/Updates
Table 105. Italfarmaco SpA Company Information
Table 106. Italfarmaco SpA Description and Business Overview
Table 107. Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
Table 109. Italfarmaco SpA Recent Developments/Updates
Table 110. Evive Biotech Company Information
Table 111. Evive Biotech Description and Business Overview
Table 112. Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
Table 114. Evive Biotech Recent Developments/Updates
Table 115. Chugai Pharmaceutical Company Information
Table 116. Chugai Pharmaceutical Description and Business Overview
Table 117. Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
Table 119. Chugai Pharmaceutical Recent Developments/Updates
Table 120. Jiangsu Hengrui Pharmaceuticals Company Information
Table 121. Jiangsu Hengrui Pharmaceuticals Description and Business Overview
Table 122. Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
Table 124. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
Table 125. Amoytop Biotech Company Information
Table 126. Amoytop Biotech Description and Business Overview
Table 127. Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
Table 129. Amoytop Biotech Recent Developments/Updates
Table 130. Qilu Pharmaceutical Company Information
Table 131. Qilu Pharmaceutical Description and Business Overview
Table 132. Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
Table 134. Qilu Pharmaceutical Recent Developments/Updates
Table 135. CSPC Baike Biopharma Company Information
Table 136. CSPC Baike Biopharma Description and Business Overview
Table 137. CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 138. CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
Table 139. CSPC Baike Biopharma Recent Developments/Updates
Table 140. SL Pharm Company Information
Table 141. SL Pharm Description and Business Overview
Table 142. SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 143. SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
Table 144. SL Pharm Recent Developments/Updates
Table 145. Lunan Pharmaceutical Company Information
Table 146. Lunan Pharmaceutical Description and Business Overview
Table 147. Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 148. Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
Table 149. Lunan Pharmaceutical Recent Developments/Updates
Table 150. Key Raw Materials Lists
Table 151. Raw Materials Key Suppliers Lists
Table 152. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Distributors List
Table 153. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Customers List
Table 154. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Trends
Table 155. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Drivers
Table 156. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Challenges
Table 157. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Restraints
Table 158. Research Programs/Design for This Report
Table 159. Key Data Information from Secondary Sources
Table 160. Key Data Information from Primary Sources
Table 161. Authors List of This Report
List of Figures
Figure 1. Product Picture of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF)
Figure 2. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Share by Type: 2025 & 2032
Figure 4. Pegfilgrastim Product Picture
Figure 5. Lenograstim Product Picture
Figure 6. Other Product Picture
Figure 7. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Value by Application (US$ Million), 2021–2032
Figure 8. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Share by Application: 2025 & 2032
Figure 9. Hospital and Clinic
Figure 10. Pharmacy
Figure 11. Other
Figure 12. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 13. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size (US$ Million), 2021–2032
Figure 14. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), 2021–2032
Figure 15. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Average Price (US$/Unit), 2021–2032
Figure 16. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Report Years Considered
Figure 17. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Share by Manufacturers in 2025
Figure 18. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Share by Manufacturers in 2025
Figure 19. Top 5 and Top 10 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Players: Market Share by Revenue in Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) in 2025
Figure 20. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 21. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 22. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2021–2032)
Figure 23. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Country (2021–2032)
Figure 24. United States Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Canada Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 26. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2021–2032)
Figure 27. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Country (2021–2032)
Figure 28. Germany Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. France Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. U.K. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Italy Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Russia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Region (2021–2032)
Figure 34. Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Region (2021–2032)
Figure 35. China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Japan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. South Korea Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. India Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Australia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. China Taiwan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Southeast Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Latin America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2021–2032)
Figure 43. Latin America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Country (2021–2032)
Figure 44. Mexico Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Brazil Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Argentina Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Colombia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2021–2032)
Figure 49. Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Country (2021–2032)
Figure 50. Turkey Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Saudi Arabia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. UAE Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Global Sales Market Share of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) by Type (2021–2032)
Figure 54. Global Revenue Market Share of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) by Type (2021–2032)
Figure 55. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price (US$/Unit) by Type (2021–2032)
Figure 56. Global Sales Market Share of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) by Application (2021–2032)
Figure 57. Global Revenue Market Share of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) by Application (2021–2032)
Figure 58. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price (US$/Unit) by Application (2021–2032)
Figure 59. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Value Chain
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Table 1. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Competitive Situation by Manufacturers in 2025
Table 4. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), Product Types and Applications
Table 12. Global Key Manufacturers of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Companies by Tier (Tier 1, Tier 2, Tier 3), based on Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (K Units), 2021–2026
Table 18. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Region (2021–2026)
Table 19. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (K Units), 2027–2032
Table 20. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Region (2027–2032)
Table 21. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region (US$ Million), 2021–2026
Table 22. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Region (2021–2026)
Table 23. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region (US$ Million), 2027–2032
Table 24. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Region (2027–2032)
Table 25. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (K Units), 2021–2026
Table 27. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (K Units), 2027–2032
Table 28. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (US$ Million), 2021–2026
Table 29. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (K Units), 2021–2026
Table 32. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (K Units), 2027–2032
Table 33. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (K Units), 2021–2026
Table 42. Latin America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (K Units), 2027–2032
Table 43. Latin America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (US$ Million), 2027–2032
Table 50. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units) by Type (2021–2026)
Table 51. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units) by Type (2027–2032)
Table 52. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2021–2026)
Table 53. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2027–2032)
Table 54. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Type (2021–2026)
Table 57. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Type (2027–2032)
Table 58. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price (US$/Unit) by Type (2021–2026)
Table 59. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price (US$/Unit) by Type (2027–2032)
Table 60. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units) by Application (2021–2026)
Table 61. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units) by Application (2027–2032)
Table 62. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Application (2021–2026)
Table 63. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Application (2027–2032)
Table 64. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Application (2021–2026)
Table 67. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Application (2027–2032)
Table 68. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price (US$/Unit) by Application (2021–2026)
Table 69. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price (US$/Unit) by Application (2027–2032)
Table 70. Amgen Company Information
Table 71. Amgen Description and Business Overview
Table 72. Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
Table 74. Amgen Recent Developments/Updates
Table 75. Mylan Company Information
Table 76. Mylan Description and Business Overview
Table 77. Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
Table 79. Mylan Recent Developments/Updates
Table 80. Kashiv BioSciences Company Information
Table 81. Kashiv BioSciences Description and Business Overview
Table 82. Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
Table 84. Kashiv BioSciences Recent Developments/Updates
Table 85. Pfizer Company Information
Table 86. Pfizer Description and Business Overview
Table 87. Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
Table 89. Pfizer Recent Developments/Updates
Table 90. Fresenius Kabi Company Information
Table 91. Fresenius Kabi Description and Business Overview
Table 92. Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
Table 94. Fresenius Kabi Recent Developments/Updates
Table 95. Coherus BioSciences Company Information
Table 96. Coherus BioSciences Description and Business Overview
Table 97. Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
Table 99. Coherus BioSciences Recent Developments/Updates
Table 100. Sandoz Company Information
Table 101. Sandoz Description and Business Overview
Table 102. Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
Table 104. Sandoz Recent Developments/Updates
Table 105. Italfarmaco SpA Company Information
Table 106. Italfarmaco SpA Description and Business Overview
Table 107. Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
Table 109. Italfarmaco SpA Recent Developments/Updates
Table 110. Evive Biotech Company Information
Table 111. Evive Biotech Description and Business Overview
Table 112. Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
Table 114. Evive Biotech Recent Developments/Updates
Table 115. Chugai Pharmaceutical Company Information
Table 116. Chugai Pharmaceutical Description and Business Overview
Table 117. Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
Table 119. Chugai Pharmaceutical Recent Developments/Updates
Table 120. Jiangsu Hengrui Pharmaceuticals Company Information
Table 121. Jiangsu Hengrui Pharmaceuticals Description and Business Overview
Table 122. Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
Table 124. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
Table 125. Amoytop Biotech Company Information
Table 126. Amoytop Biotech Description and Business Overview
Table 127. Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
Table 129. Amoytop Biotech Recent Developments/Updates
Table 130. Qilu Pharmaceutical Company Information
Table 131. Qilu Pharmaceutical Description and Business Overview
Table 132. Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
Table 134. Qilu Pharmaceutical Recent Developments/Updates
Table 135. CSPC Baike Biopharma Company Information
Table 136. CSPC Baike Biopharma Description and Business Overview
Table 137. CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 138. CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
Table 139. CSPC Baike Biopharma Recent Developments/Updates
Table 140. SL Pharm Company Information
Table 141. SL Pharm Description and Business Overview
Table 142. SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 143. SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
Table 144. SL Pharm Recent Developments/Updates
Table 145. Lunan Pharmaceutical Company Information
Table 146. Lunan Pharmaceutical Description and Business Overview
Table 147. Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 148. Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product
Table 149. Lunan Pharmaceutical Recent Developments/Updates
Table 150. Key Raw Materials Lists
Table 151. Raw Materials Key Suppliers Lists
Table 152. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Distributors List
Table 153. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Customers List
Table 154. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Trends
Table 155. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Drivers
Table 156. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Challenges
Table 157. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Restraints
Table 158. Research Programs/Design for This Report
Table 159. Key Data Information from Secondary Sources
Table 160. Key Data Information from Primary Sources
Table 161. Authors List of This Report
List of Figures
Figure 1. Product Picture of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF)
Figure 2. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Share by Type: 2025 & 2032
Figure 4. Pegfilgrastim Product Picture
Figure 5. Lenograstim Product Picture
Figure 6. Other Product Picture
Figure 7. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Value by Application (US$ Million), 2021–2032
Figure 8. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Share by Application: 2025 & 2032
Figure 9. Hospital and Clinic
Figure 10. Pharmacy
Figure 11. Other
Figure 12. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 13. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size (US$ Million), 2021–2032
Figure 14. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), 2021–2032
Figure 15. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Average Price (US$/Unit), 2021–2032
Figure 16. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Report Years Considered
Figure 17. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Share by Manufacturers in 2025
Figure 18. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Share by Manufacturers in 2025
Figure 19. Top 5 and Top 10 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Players: Market Share by Revenue in Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) in 2025
Figure 20. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 21. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 22. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2021–2032)
Figure 23. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Country (2021–2032)
Figure 24. United States Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Canada Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 26. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2021–2032)
Figure 27. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Country (2021–2032)
Figure 28. Germany Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. France Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. U.K. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Italy Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Russia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Region (2021–2032)
Figure 34. Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Region (2021–2032)
Figure 35. China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Japan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. South Korea Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. India Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Australia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. China Taiwan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Southeast Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Latin America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2021–2032)
Figure 43. Latin America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Country (2021–2032)
Figure 44. Mexico Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Brazil Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Argentina Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Colombia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2021–2032)
Figure 49. Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Country (2021–2032)
Figure 50. Turkey Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Saudi Arabia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. UAE Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Global Sales Market Share of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) by Type (2021–2032)
Figure 54. Global Revenue Market Share of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) by Type (2021–2032)
Figure 55. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price (US$/Unit) by Type (2021–2032)
Figure 56. Global Sales Market Share of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) by Application (2021–2032)
Figure 57. Global Revenue Market Share of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) by Application (2021–2032)
Figure 58. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price (US$/Unit) by Application (2021–2032)
Figure 59. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Value Chain
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Sales Planning Tool Market Research Report 2026
Feb 03, 26
Global Chromium Oxide Powder Market Research Report 2026
Feb 03, 26
Global Shape Memory Actuator Market Research Report 2026
Feb 03, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232